Antiparkinsonian Efficacy of Guanosine in Rodent Models of Movement Disorder.

about

Neuromodulatory Effects of Guanine-Based Purines in Health and Disease

P2860

Q59127756-F35DC30C-A556-46E9-AC79-0D80E93529E6

P2860

Antiparkinsonian Efficacy of Guanosine in Rodent Models of Movement Disorder.

Item

http://www.wikidata.org/entity/Q42372900

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Antiparkinsonian Efficacy of Guanosine in Rodent Models of Movement Disorder.

@en

Antiparkinsonian Efficacy of Guanosine in Rodent Models of Movement Disorder.

@nl

type

Item

label

Antiparkinsonian Efficacy of Guanosine in Rodent Models of Movement Disorder.

@en

Antiparkinsonian Efficacy of Guanosine in Rodent Models of Movement Disorder.

@nl

prefLabel

Antiparkinsonian Efficacy of Guanosine in Rodent Models of Movement Disorder.

@en

Antiparkinsonian Efficacy of Guanosine in Rodent Models of Movement Disorder.

@nl

P1476

Antiparkinsonian Efficacy of Guanosine in Rodent Models of Movement Disorder

@en

P2093

Fabiana Núñez

http://www.w3.org/2001/XMLSchema#string

Francisco Ciruela

http://www.w3.org/2001/XMLSchema#string

Marc López-Cano

http://www.w3.org/2001/XMLSchema#string

Víctor Fernández-Dueñas

http://www.w3.org/2001/XMLSchema#string

P2860

Guanosine: a Neuromodulator with Therapeutic Potential in Brain Disorders

Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease

Characterization of the Potent and Highly Selective A(2A) Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyraz olo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in Rodent Models of

L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.

Mechanisms involved in the antinociception induced by systemic administration of guanosine in mice.

The spectrum of levodopa-induced dyskinesias.

Trophic effects of purines in neurons and glial cells.

3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists.

Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature.

Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease.

P304

700

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FPHAR.2017.00700

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Caio M Massari

C I Tasca

P577

2017-10-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29046640

http://www.w3.org/2001/XMLSchema#string

P932

5632808

http://www.w3.org/2001/XMLSchema#string

Antiparkinsonian Efficacy of Guanosine in Rodent Models of Movement Disorder.

about

P2860

P2860

Antiparkinsonian Efficacy of Guanosine in Rodent Models of Movement Disorder.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P932